‹ All Posts
Adarsh Nimborkar

30 mins ago · SEBI Registration INA000019789

Indoco Remedies Ltd Growth & Operational Recovery

INDOCO Indoco Remedies Ltd. is an Indian pharmaceutical company engaged in manufacturing and marketing formulations and Active Pharmaceutical Ingredients (APIs) across domestic and international markets. Its portfolio covers respiratory, gastrointestinal, ophthalmic, dental, dermatology and other therapeutic segments. The company has an established presence in regulated international markets, particularly the US and Europe, providing opportunities for geographical diversification and long-term growth. For Q2 FY27, consolidated revenue increased 7.4% YoY to ₹506.9 crore. EBITDA improved 7.7% to ₹46.4 crore, while EBITDA margin remained broadly stable at 9.2%. Net profit recovered to ₹18.4 crore compared with a net loss of ₹7.9 crore in the corresponding quarter last year. For H1 FY27, revenue grew 7.8%, while EBITDA increased significantly by 44.4%, indicating an improvement in operating performance. International formulations business delivered strong growth of 21.1% during Q2 FY27, while API and allied services recorded growth of 22% and 27.4%, respectively, during H1. These segments could become important growth drivers. However, regulatory compliance remains a key concern, particularly following seven procedural observations received from the USFDA for its Goa Plant 1. Resolution of these observations will be important for restoring operational confidence. Overall, Indoco Remedies is showing signs of financial recovery, supported by improving profitability, international business growth and operational efficiencies. However, consistent revenue growth, margin expansion and successful resolution of regulatory concerns remain critical. The company deserves monitoring, but investors should avoid assuming that one profitable quarter confirms a sustained turnaround. The coming quarters will be crucial in establishing the durability of its recovery.

#EquityResearch#HiddenGems#FundamentalViews#StockInNews#WatchOutFor
1 like